Krystal Biotech receives approval in Europe for gene therapy treatment

Shares of Krystal Biotech Inc. were up 27% in Monday intraday trade after the gene therapy company said it had receive.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Krystal Biotech announced Tuesday that it had named Jennifer Chien to the newly created position of chief commercial officer, effective Monday. Chien joins the Pittsburgh-based gene therapy company after serving as vice president, head of geneti.....»»

A gene therapy invented at Nationwide Children's Hospital just landed a licensing deal worth as much as $2.8 billion for a Boston biotech, and now the company's Columbus office will play a big role in getting the treatment to the market. Sarepta Th.....»»

Novartis plans to answer a U.S. senator who demanded details about data manipulation related to its gene therapy Zolgensma, amid scrutiny of the Swiss drugmaker's decision to delay informing regulators until after the treatment's approval......»»

A Novartis AG unit that developed a breakthrough gene therapy knew about potential manipulation of animal testing data but failed to disclose it to regulators before the treatment was approved, the U.S. Food and Drug Administration said......»»

Krystal Biotech Inc (NASDAQ: KRYS) shares spiked after the gene therapy company announcing positive results from its KB103 clinical trial on Monday.  The stock was higher by 46.11% at $42.59 at the time of publication Monday.  read more.....»»

Merck (MRK) receives approval for Keytruda's combo therapy for first-line treatment of metastatic squamous non-small cell lung cancer po.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Reader Inquiry: Why Is Krystal Biotech Not Participating In The Rally In Gene Therapy Stocks?.....»»

Novartis (NVS) gets EC approval for CAR-T therapy, Kymriah, for the treatment of pediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukemia. Novartis AG NVS announced that the European Commiss.....»»

Krystal Biotech: An Intriguing Gene Therapy Platform Play.....»»

Zacks.....»»

Clovis Oncology (CLVS) announces approval of label expansion for Rubraca to include maintenance treatment of ovarian cancer pati.....»»

Fardis had guided Iovance from being a little-know startup to the cusp of having an approved treatment. But the FDA request will set back its approval process by two years......»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

A Durham biotech startup that spun out of Duke University has raised $7 million in seed funding to scale up its purification technology for biotherapeutics. Isolere Bio Inc. announced Wednesday it has raised $7 million in equity from lead inve.....»»

A gene therapy startup that launched last summer has raised $120 million toward expanding its biotech manufacturing capacity in Grove City. It's the largest Series B financing in Ohio history, according to PitchBook......»»

Vertex Pharmaceuticals Inc. said Tuesday it plans to pay $1.1 billion to Crispr Therapeutics AG as part of a deal to test an experimental gene-editing therapy for sickle cell disease and transfusion-dependent beta-tha.....»»